BnoX™ our latest product developed for pain management, is a sublingual buprenorphine wafer formulated for the treatment of moderate to severe pain. With the spotlight currently on the global opioid epidemic, there is now an increasing recognition that buprenorphine can be a critical and emerging compound for pain management.
Buprenorphine has been shown to provide longer lasting pain relief with fewer side effects compared to other opioids. It also exhibits a ceiling effect – higher doses do not result in unwanted additional opioid effects, including euphoria and respiratory depression. Patients are therefore less likely to develop addiction and tolerance, while the risk of death is also greatly reduced.
Buprenorphine is known for its poor bioavailability (reported to be 10% or less) when ingested orally. However, by utilising iX Biopharma’s proprietary sublingual technology WaferiX™, we have demonstrated in a phase 1 pharmacokinetic study (BUP001) that BnoX™ facilitates the rapid absorption of buprenorphine (median Tmax 1.0 hour) with greater absolute bioavailability of 45%. These results suggest superior pharmacokinetics to currently marketed sublingual buprenorphine formulations.
In 2017, we launched Bnox™ and the product is now being supplied to hospitals and registered pharmacies in Australia under Schedule 5A of the Therapeutic Goods Administration (TGA).